{"id":"W2883546793","doi":"10.1002/jcph.1107","title":"Cardiovascular Safety of the β<sub>3</sub>‐Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial","year":2018,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Allergan; Astellas Pharma Global Development; Astellas Foundation for Research on Metabolic Disorders; Ipsen; Pfizer","keywords":"Mirabegron; Solifenacin; Medicine; Placebo; Overactive bladder; Combination therapy; Urology; Internal medicine; Pharmacology; Anesthesia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01989228,0.0001683279,0.000972306,0.0000667983,0.0002541338,0.0000149698,0.0007622288,0.0001456029,0.0001292202],"category_scores_gemma":[0.0008968962,0.00006034247,0.0008534778,0.0002958979,0.002670803,0.00005167232,0.0002643139,0.001611463,0.00001007859],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000337612,"about_ca_system_score_gemma":0.000473208,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004597756,"about_ca_topic_score_gemma":0.00001806746,"domain_scores_codex":[0.9908768,0.006341489,0.00152123,0.0001702709,0.0007335366,0.0003566576],"domain_scores_gemma":[0.9938361,0.004707364,0.0005581573,0.0004955812,0.0002718805,0.0001308869],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.793128,0.003274053,0.005946549,0.0002549882,0.0100634,0.0003822792,0.007474673,0.0002526806,0.0232673,0.0003105681,0.06911436,0.08653113],"study_design_scores_gemma":[0.4964798,0.02549543,0.2072503,0.0003824357,0.01126012,0.003744798,0.002444156,0.001286198,0.04400288,0.002396225,0.2047185,0.00053913],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9724117,0.003268928,0.00002929073,0.02034472,0.00197587,0.001058723,0.000005813316,0.000003529734,0.0009014463],"genre_scores_gemma":[0.9826451,0.01147938,0.000008969575,0.002516557,0.003264549,0.000008325781,7.753329e-7,0.00001615363,0.00006021259],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2966482,"threshold_uncertainty_score":0.9840686,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.063444621870896,"score_gpt":0.4039625429456552,"score_spread":0.3405179210747592,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}